Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro

Bone

Volumn 50, Issue 3, 2012, Pages 798-803

  Heervä, Eetu ^a   Peltonen, Sirkku ^b   Svedström, Erkki ^a   Aro, Hannu T ^b   Väänänen, Kalervo ^a   Peltonen, Juha ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

BTM; Farnesyl thiosalicylic acid; Fracture; Neurofibromatosis; Osteoporosis

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; CLODRONIC ACID; PROTEIN INHIBITOR; RAS PROTEIN; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BONE DENSITY; BONE EXAMINATION; BONE TURNOVER; CELL ACTIVITY; CELL COUNT; CELL ISOLATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NEUROFIBROMATOSIS; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK FACTOR;

ADULT; AGED; ALENDRONATE; BIOLOGICAL MARKERS; BONE DENSITY; BONE RESORPTION; CELLS, CULTURED; CLODRONIC ACID; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; NEUROFIBROMATOSIS 1; OSTEOCLASTS; OSTEOPOROSIS;

EID: 84856956439     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.12.011     Document Type: Article

References (35)

1. Riccardi V.M., Eichner J.E. Neurofibromatosis: phenotype 1986, Natural History and Pathogenesis, Johns Hopkins University Press, Baltimore, MD, USA.
2. Lammert M., Friedman J., Kluwe L., Mautner V. Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol 2005, 141:71-74.
3. Jouhilahti E.M., Peltonen S., Heape A.M., Peltonen J. The pathoetiology of neurofibromatosis 1. Am J Pathol 2011, 178:1932-1939.
4. Xu G., O'Connell P., Viskochil D., Cawthon R., Robertson M., Culver M., Dunn D., Stevens J., Gesteland R., White R. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990, 62:599-608.
5. Leskelä H., Kuorilehto T., Risteli J., Koivunen J., Nissinen M., Peltonen S., Kinnunen P., Messiaen L., Lehenkari P., Peltonen J. Congenital pseudarthrosis of neurofibromatosis type 1: impaired osteoblast differentiation and function and altered NF1 gene expression. Bone 2009, 44:243-250.
6. Elefteriou F., Kolanczyk M., Schindeler A., Viskochil D., Hock J., Schorry E., Crawford A., Friedman J., Little D., Peltonen J., Carey J., Feldman D., Yu X., Armstrong L., Birch P., Kendler D., Mundlos S., Yang F., Agiostratidou G., Hunter-Schaedle K., Stevenson D. Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options. Am J Med Genet A 2009.
7. Kuorilehto T., Pöyhönen M., Bloigu R., Heikkinen J., Väänänen K., Peltonen J. Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body. Osteoporos Int 2005, 16:928-936.
8. Stevenson D.A., Moyer-Mileur L.J., Murray M., Slater H., Sheng X., Carey J.C., Dube B., Viskochil D.H. Bone mineral density in children and adolescents with neurofibromatosis type 1. J Pediatr 2007, 150:83-88.
9. Duman O., Ozdem S., Turkkahraman D., Olgac N.D., Gungor F., Haspolat S. Bone metabolism markers and bone mineral density in children with neurofibromatosis type-1. Brain Dev 2008, 30:584-588.
10. Brunetti-Pierri N., Doty S.B., Hicks J., Phan K., Mendoza-Londono R., Blazo M., Tran A., Carter S., Lewis R.A., Plon S.E., Phillips W.A., O'Brian Smith E., Ellis K.J., Lee B. Generalized metabolic bone disease in neurofibromatosis type I. Mol Genet Metab 2008, 94:105-111.
11. Seitz S., Schnabel C., Busse B., Schmidt H.U., Beil F.T., Friedrich R.E., Schinke T., Mautner V.F., Amling M. High bone turnover and accumulation of osteoid in patients with neurofibromatosis 1. Osteoporos Int 2010, 21:119-127.
12. Tucker T., Schnabel C., Hartmann M., Friedrich R.E., Frieling I., Kruse H.P., Mautner V.F., Friedman J.M. Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1). J Med Genet 2009, 46:259-265.
13. Stevenson D.A., Yan J., He Y., Li H., Liu Y., Zhang Q., Jing Y., Guo Z., Zhang W., Yang D., Wu X., Hanson H., Li X., Staser K., Viskochil D.H., Carey J.C., Chen S., Miller L., Roberson K., Moyer-Mileur L., Yu M., Schwarz E.L., Pasquali M., Yang F.C. Multiple increased osteoclast functions in individuals with neurofibromatosis type 1. Am J Med Genet A 2011, 155A:1050-1059.
14. Glover S.J., Gall M., Schoenborn-Kellenberger O., Wagener M., Garnero P., Boonen S., Cauley J.A., Black D.M., Delmas P.D., Eastell R. Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res 2009, 24:389-397.
15. Vasikaran S., Eastell R., Bruyère O., Foldes A.J., Garnero P., Griesmacher A., McClung M., Morris H.A., Silverman S., Trenti T., Wahl D.A., Cooper C., Kanis J.A., Group I.-I.B.M.S.W. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011, 22:391-420.
16. Reszka A.A., Rodan G.A. Mechanism of action of bisphosphonates. Curr Osteoporos Rep 2003, 1:45-52.
17. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003, 9:2643-2658.
18. Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D.D., Golub E., Rodan G.A. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991, 88:2095-2105.
19. Fujita H., Utsumi T., Muranaka S., Ogino T., Yano H., Akiyama J., Yasuda T., Utsumi K. Involvement of Ras/extracellular signal-regulated kinase, but not Akt pathway in risedronate-induced apoptosis of U937 cells and its suppression by cytochalasin B. Biochem Pharmacol 2005, 69:1773-1784.
20. Bergstrom J.D., Bostedor R.G., Masarachia P.J., Reszka A.A., Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000, 373:231-241.
21. Dunford J.E., Rogers M.J., Ebetino F.H., Phipps R.J., Coxon F.P. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. J Bone Miner Res 2006, 21:684-694.
22. Scheven B., Visser J., Nijweide P. In vitro osteoclast generation from different bone marrow fractions, including a highly enriched haematopoietic stem cell population. Nature 1986, 321:79-81.
23. Massey H., Flanagan A. Human osteoclasts derive from CD14-positive monocytes. Br J Haematol 1999, 106:167-170.
24. Tiedemann K., Hussein O., Sadvakassova G., Guo Y., Siegel P., Komarova S. Breast cancer-derived factors stimulate osteoclastogenesis through the Ca2+/protein kinase C and transforming growth factor-beta/MAPK signaling pathways. J Biol Chem 2009, 284:33662-33670.
25. Yang F., Chen S., Robling A., Yu X., Nebesio T., Yan J., Morgan T., Li X., Yuan J., Hock J., Ingram D., Clapp D. Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J Clin Invest 2006, 116:2880-2891.
26. Heervä E., Alanne M.H., Peltonen S., Kuorilehto T., Hentunen T., Väänänen K., Peltonen J. Osteoclasts in neurofibromatosis type 1 display enhanced resorption capacity, aberrant morphology, and resistance to serum deprivation. Bone 2010, 47:583-590.
27. Ma J., Li M., Hock J., Yu X. Hyperactivation of mTOR critically regulates abnormal osteoclastogenesis in neurofibromatosis type 1. J Orthop Res 2011.
28. Schindeler A., Birke O., Yu N.Y., Morse A., Ruys A., Baldock P.A., Little D.G. Distal tibial fracture repair in a neurofibromatosis type 1-deficient mouse treated with recombinant bone morphogenetic protein and a bisphosphonate. J Bone Joint Surg Br 2011, 93:1134-1139.
29. Stumpf D., Annergers J., Brown S., Conneally P., Housman D., Leppert M., Miller J., Moss M., Pileggi A., Rapin I., Strohman R., Swanson L., Zimmersman A. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988, 45:575-578.
30. Consensus N.I.H. Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001, 285:785-795.
31. Lewiecki E.M., Gordon C.M., Baim S., Binkley N., Bilezikian J.P., Kendler D.L., Hans D.B., Silverman S., Bishop N.J., Leonard M.B., Bianchi M.L., Kalkwarf H.J., Langman C.B., Plotkin H., Rauch F., Zemel B.S. Special report on the 2007 adult and pediatric Position Development Conferences of the International Society for Clinical Densitometry. Osteoporos Int 2008, 19:1369-1378.
32. Hentunen T.A., Reddy S.V., Boyce B.F., Devlin R., Park H.R., Chung H., Selander K.S., Dallas M., Kurihara N., Galson D.L., Goldring S.R., Koop B.A., Windle J.J., Roodman G.D. Immortalization of osteoclast precursors by targeting Bcl-XL and Simian virus 40 large T antigen to the osteoclast lineage in transgenic mice. J Clin Invest 1998, 102:88-97.
33. Chopin F., Biver E., Funck-Brentano T., Bouvard B., Coiffier G., Garnero P., Thomas T. Prognostic interest of bone turnover markers in the management of postmenopausal osteoporosis. Joint Bone Spine 2011, 30.
34. Adami S., Isaia G., Luisetto G., Minisola S., Sinigaglia L., Gentilella R., Agnusdei D., Iori N., Nuti R., Group I.S. Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res 2006, 21:1565-1570.
35. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., Cosman F., Lakatos P., Leung P.C., Man Z., Mautalen C., Mesenbrink P., Hu H., Caminis J., Tong K., Rosario-Jansen T., Krasnow J., Hue T.F., Sellmeyer D., Eriksen E.F., Cummings S.R., Trial H.P.F. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.